

## UTAH DEPARTMENT OF HEALTH



STATE MEDICAID PHARMACY AND THERAPEUTICS COMMITTEE
Thursday, April 17, 2014
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 128

## **AGENDA**

Please note that persons who wish to address the P&T Committee may contact Lisa V. Hunt (<a href="lvhunt@utah.gov">lvhunt@utah.gov</a>) at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints

1)	Welcome and Introductions	
	b) Update on PDL Administration	
2)	DUR Board Update	
3)	April 2014 Review: Annual Open Public Meetings Act TrainingBrody McKelvey, J.D.	
4)	Scopolamine and related products or related products	
	b) Board Discussion/Questions c) Other States Report	
	d) Board Action	
5)	Epipen formulations	
	Included agents: Adrenaclick, Auvi-Q, EpiPen, EpiPen Jr, epinephrine, and similar or related products	
	a) Public Comment	
	b) Board Discussion/Questions	
	c) Other States Report	
	d) Board Action	
6)	Next Meeting May 15, 2014 (Antihistamines 1 <sup>st</sup> and 2 <sup>nd</sup> generation products)	
7)	Adjourned	

Public comment that responds to the materials presented by the College of Pharmacy @University of Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-based Practice Center or the University of Utah, College of Pharmacy, and are posted in advance on the P&T Committee website. Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:

Dr. Gary Oderda College of Pharmacy 30 South 2000 East SLC, UT 84112-5820

All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.

Month	Topic	Agents
5/22/2014	Antihistamines 1 <sup>st</sup> Generation Agents	Brompheniramine, Carbinoxamine, Chlorpheniramine, Clemastine, Cyclizine, Cyproheptadine, Dexchlorpheniramine, Dimenhydrinate, Diphenhydramine, Doxylamine, Hydroxyzine *including all combination agents
	Antihistamines 2 <sup>nd</sup> Generation Agents	Cetirizine, Desloratadine, Fexofenadine, Ketotifen, Levocetirizine, Loratadine *including all combination agents
6/19/2014	No Meeting	N/A
7/17/2014	Vitamin D Analogs	Alfacalcidol, Calcitriol, Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol
//1//2014	Bile Acid Sequestrants	Cholestyramine Resin, Colesevelam, Colestipol
	Amebicide Anti- Infective Agents	Iodoquinol, Metronidazole, Metronidazole/Nystatin, Tinidazole
8/21/2014	Macrolide Antibiotics	Azithromycin, Clarithromycin, Erythromycin, Erythromycin/Sulfisoxazole, Fidaxomicin, Lansoprazole/Amoxicillin/Clarithromycin, Omeprazole/Clarithromycin/Amoxicillin
	Aminoglycosides	Amikacin, Gentamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin
9/18/2014	Tetracyclines	Demeclocycline, Doxycycline, Doxycycline Hyclate, Minocycline, Minocycline Hydrochloride, Tetracycline *including all combination agents
10/16/2014	Thiazide Diuretic Agents	Chlorothiazide, Chlorthalidone, Hydrochlorothiazide, Methyclothiazide, Indapamide, Metolazone
	Loop Diuretics	Bumetanide, Ethacrynic Acid, Furosemide, Torsemide
11/20/2014	Potassium-Sparing Diuretics	Amiloride, Eplerenone, Spironolactone, Triamterene
11/20/2014	Agents used to treat Angina	Nitroglycerin, Ranolazine, Amyl Nitrite, Isosorbide Dinitrate, Isosorbide Mononitrate
12/18/2014	Beta-Lactams and Clavulanate Combos	Amoxicillin, Amoxicillin/Clavulanate, Ampicillin, Ampicillin/Sulbactam, Cloxacillin, Dicloxacillin, Nafcillin, Oxacillin, Penicillin, Piperacillin, Piperacillin/Tazobactam, Ticarcillin/Clavulanate